Metrics as of 10/14/2026, 06:00 PM (Berlin time), refresh in progress.
IDEAYA Biosciences Stock
IDEAYA Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Yujiro S. Hata
- Employees
- 145
- Market cap
- $3.3 B
- IPO
- 23/05/2019
IDEAYA Biosciences, Inc. is a healthcare company headquartered in South San Francisco, USA. Founded in 2015, the firm is listed on the NASDAQ and operates within the biotechnology industry. The company is primarily dedicated to precision oncology by identifying and advancing targeted therapies, specifically leveraging…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
IDEAYA Biosciences stock: price history
1D
-1.2%
1W
-6.6%
1M
-11.0%
6M
+5.2%
YTD
-2.1%
1Y
+25.1%
2Y
+11.1%
5Y
+46.4%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~18% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
IDEAYA Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
2 more assignments (Enabler/Second row) Pro-only.
IDEAYA Biosciences is a biotechnology company specializing in precision oncology that pursues the development of targeted therapies through the principle of synthetic lethality. The company uses molecular diagnostic procedures to identify and treat patients with specific genetic mutations. The clinical pipeline includes therapeutics against tumors with MTAP deletions or GNAQ gene mutations as well as programs for treating BRCA or MSI H associated cancers. Through strategic alliances with Pfizer Inc. and GlaxoSmithKline plc as well as research collaborations, development is being advanced. The current business model is based entirely on research and development services within the framework of these partnerships.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- High
Suppliers & customers in our universe
Pfizer Inc.DescriptionAsk the agents about IDEAYA Biosciences
Analyst assessment of IDEAYA Biosciences
PRICE TARGET LOW
US$48.00
CONSENSUS
US$57.00
MEDIAN
US$58.50
PRICE TARGET HIGH
US$63.00
0
STRONG BUY
24
BUY
2
HOLD
0
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 09/09/2026
IDEAYA Biosciences stock metrics
P/E
-17.64
P/B
2.6
EV/EBITDA
-16.64
RETURN ON EQUITY
-9.4%
NET MARGIN
-1,269.6%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.4%
FLOAT SHARES
90,079,703
AVG. DAILY VOLUME (30D)
813,396
Insider transactions (SEC)
Hata Yujiro S
Hata Yujiro S
Hata Yujiro S
Ruiz Briseno Andres
Ruiz Briseno Andres
Institutional holders
Comparable stocks
Frequently asked questions about IDEAYA Biosciences stock
What does IDEAYA Biosciences do?
IDEAYA Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Yujiro S. Hata, the company employs around 145 people.
The IPO was on 23/05/2019; the stock trades on NASDAQ under the ticker IDYA.
What do analysts say about IDEAYA Biosciences stock?
26 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$57.00, ranging from US$48.00 to US$63.00, with a median of US$58.50.
This is an external assessment, not a statement by Market Jury.
When does IDEAYA Biosciences report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does IDEAYA Biosciences pay a dividend?
No, IDEAYA Biosciences currently does not pay a dividend.
Which stocks are comparable to IDEAYA Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get IDEAYA Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess IDEAYA Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.